NCT06272058View on ClinicalTrials.gov

A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 3, 2024

Primary Completion Date

July 2, 2024

Study Completion Date

July 2, 2024

Conditions
HealthyLiver Diseases
Interventions
DRUG

Avenciguat (BI 685509)

Avenciguat (BI 685509)

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

78215

American Research Corporation at the Texas Liver Institute, San Antonio

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY